Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors
Metadata only so far. Questions are answered only with quotes from this document. Source: ClinicalTrials.gov, retrieved 2026-11-04.
Ongoing
Record metadata
- Phase
- Phase 1 / Phase 2
- Status
- Recruiting
- Start
- 2026-10-22
- End
- 2029-04-30
- Enrollment
- 320
- Sites
- 1
- Sponsor class
- INDUSTRY
Not in the data yet: a trial card. A one-glance card (population, design, endpoints, result, each tied to a quote) is not built yet. The fields above are registry or bibliographic metadata, not quotes.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you get that instead of a guess.
Source text
No passages are loaded for this document yet.